More Neuren Pharmaceuticals Limited news
Neuren Pharmaceuticals LimitedASX: NEU

FDA grants Orphan Drug Designation for NNZ-2591 in Angelman

Oct 11, 2019 at 2:42 AM EDT · Issued by Neuren Pharmaceuticals Limited

Filed with ASX · Oct 11, 2019 at 2:42 AM EDT · 2 pages · English

On 6ix: 6ix.com/news/fda-grants-orphan-drug-designation-for-nnz-2591-in-angelman

Neuren Pharmaceuticals Limited on 6ix

Story so far

  • NNZ-2591 positive effects in Angelman syndrome modelMay 17, 2019

Earlier from Neuren Pharmaceuticals

  • Neuren approaching key milestones in Q4 2019Sep 20, 2019
  • NNZ-2591 positive effects in Pitt Hopkins syndrome modelMay 17, 2019
  • NNZ-2591 positive effects in Angelman syndrome modelMay 16, 2019
  • Update on development plan for NNZ-2591Apr 26, 2019
  • Neurens Rett syndrome Phase 2 trial published in NeurologyMar 27, 2019

Later from Neuren Pharmaceuticals

  • FDA grants Orphan for both Phelan-McDermid and Pitt HopkinsOct 15, 2019
  • FDA Grants Orphan Drug Designation for Neuren's NNZ-2591 to Treat Angelman, Phelan-McDermid and Pitt Hopkins SyndromesOct 17, 2019
  • Phase 3 trial of trofinetide in Rett syndrome commencesOct 30, 2019
  • Patent to 2034 granted in Europe for Neurens NNZ-2591Dec 2, 2019
  • 2019 year-end update and 2020 outlookDec 11, 2019
All Neuren Pharmaceuticals news releases↗

Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.

Follow Neuren Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer